Prophylactic Intraventricular Vancomycin for Prevention of External Ventricular Drain-Related Infections: A Retrospective Cohort Study
International Journal of Pharmaceutical Quality Assurance · 30.10.2026 · 17 (10)
DOI: 10.25258/ijpqa.17.10.2 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.10.2026. Verfasst von Malavsinh Jadeja und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
External ventricular drain (EVD)-related infection (ERI) is a significant complication of neurosurgical care, contributing to morbidity, prolonged hospitalization, and increased healthcare costs. Although intraventricular vancomycin can achieve high cerebrospinal fluid concentrations, its prophylactic role and potential effect on microbial patterns remain insufficiently characterized.
Objective
To evaluate the feasibility and preliminary association of adjunctive intraventricular vancomycin with intravenous cephalosporin, compared with intravenous cephalosporin alone, in reducing ERI among adults undergoing EVD placement.
Methods
In this retrospective cohort study, 90 adults undergoing EVD placement were allocated equally to receive intraventricular vancomycin 10 mg daily for 7 days plus intravenous ceftriaxone or ceftazidime, or intravenous cephalosporin alone. The primary outcome was ERI within 30 days. Secondary outcomes included ICU and hospital length of stay, microbial profile, EVD duration and replacement, mortality, and adverse events.
Results
ERI occurred in 3/45 patients (6.7%) receiving vancomycin versus 12/45 (26.7%) controls (absolute risk reduction, 20.0%; 95% CI, 5.2–34.8%; RR, 0.25; 95% CI, 0.08–0.81; p=0.02). All infections in the vancomycin group were caused by gram-negative organisms compared with 2/12 (16.7%) in controls (p=0.02). Hospital and ICU stays were significantly shorter with vancomycin. Transient chemical ventriculitis occurred in 2 patients (4.4%). Mortality was 11.1% versus 26.7% (p=0.10).
Conclusion
Adjunctive intraventricular vancomycin was associated with lower ERI rates and shorter hospital and ICU stays but with a shift toward gram-negative infections. Given the small, retrospective sample, these findings are preliminary and hypothesis-generating. Larger multicenter studies are warranted to confirm efficacy, safety, and microbial consequences.
Zitieren
APA
Jadeja, M., Bhatnagar, N., Meena, R. V., Mangal, G., Chhabra, A., & Partani, S. (2026). Prophylactic Intraventricular Vancomycin for Prevention of External Ventricular Drain-Related Infections: A Retrospective Cohort Study. International Journal of Pharmaceutical Quality Assurance, 17(10). https://doi.org/10.25258/ijpqa.17.10.2
Vancouver
Jadeja M, Bhatnagar N, Meena RV, Mangal G, Chhabra A, Partani S. Prophylactic Intraventricular Vancomycin for Prevention of External Ventricular Drain-Related Infections: A Retrospective Cohort Study. International Journal of Pharmaceutical Quality Assurance. 2026;17(10). doi:10.25258/ijpqa.17.10.2
BibTeX
@article{Jadeja2026,
author = {Jadeja, Malavsinh and Bhatnagar, Neelesh and Meena, Ram Velash and Mangal, Govind and Chhabra, Alka and Partani, Seema},
title = {Prophylactic Intraventricular Vancomycin for Prevention of External Ventricular Drain-Related Infections: A Retrospective Cohort Study},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {10},
doi = {10.25258/ijpqa.17.10.2}
}
EUVIMED